WASHINGTON, Nov. 8, 2019 /PRNewswire/ -- Trio Health, a
leading provider of real-world evidence, today announced results
from four studies presented at the Liver Meeting of the American
Association for the Study of Liver Diseases.
Founded in 2013, Trio tracks a patient through the entire
treatment journey by combining disparate information from the
physician, pharmacy, and payer 'trio,' to produce comprehensive and
high-quality databases that are on caliber with FDA-level
rigor.
"These studies highlight Trio Health's continued commitment to
understand care of real-world patients with viral hepatitis,'' said
Scott Milligan, PhD, Head of
Analytics, Trio Health. "Since our initial HCV studies in 2013,
we've observed repeating themes across diseases where new, more
efficacious, and safer therapies have been approved; namely,
challenges in access to these therapies, understanding potential
effects of long-term treatment with newer therapies, and potential
concerns with the use of these therapies in diseases with changing
population demographics."
FRI-0486 - DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION
IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL
PRACTICE - Lead Author: Michael
Curry, MD
Previously, Trio Health reported increased HBV suppression, ALT
normalization, and improved renal function in patients who were
treated with tenofovir alafenamide (TAF), the most recently
approved drug for HBV. However, certain patients that would
potentially benefit from switching to TAF, those with
osteopenia/osteoporosis, suboptimal eGFR, elevated ALT, or advanced
liver fibrosis, remained on non-TAF therapies at the time of that
study. In this follow up study of 1037 patients, TAF adoption in
the 2 years since approval was <50% in patients with
osteopenia/osteoporosis, suboptimal eGFR, elevated ALT, or advanced
liver fibrosis. Notably, adoption was similar in patients without
these disease features, suggesting that the presence of these risk
factors was insufficient for access.
FRI-0487 - LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE
(TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA
SUPPRESSION - Lead author: K. Rajender
Reddy, MD
This study evaluated virologic suppression rates, eGFR,
fibrosis, and ALT in 270 patients on longer term (48+ weeks) TAF
therapy for Hepatitis B in U.S. clinical practice. Statistically
significant improvements occurred in HBV DNA suppression and mean
ALT. In this population, changes in mean eGFR and fibrosis severity
did not reach significance at 48+ weeks compared to baseline.
However, 22% of patients with renal impairment (eGFR <60 ml/min)
improved to eGFR >60 ml/min at 48+ weeks and 19% of patients
with moderate to severe fibrosis at baseline improved to low to
moderate fibrosis at 48+ weeks.
SUN-1500 - PANGENOTYPIC THERAPIES GLECAPREVIR-PIBRENTASVIR
(GLE-PIB) AND SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR (SOF-VEL-VOX)
AFTER FAILURE WITH INTERFERON (IFN)-FREE DIRECT-ACTING ANTIVIRAL
(DAA) TREATMENT FOR HEPATITIS C - Lead author: Steven L Flamm,
MD
Despite the remarkable effectiveness of IFN-free DAA treatment
in real-world HCV care, treatment failures remain a challenge in
disease eradication. In this study, HCV-infected patients with
prior DAA failure/relapse achieved significantly higher intent to
treat (ITT) and per protocol (PP) SVR rates with SOF-VEL-VOX
compared to GLE-PIB both before and after adjustment for clinical
differences.
SUN-1503 - DRUG-DRUG INTERACTIONS (DDIs) WITH PANGENOTYPIC
DIRECT-ACTING ANTIVIRALS (DAAs) IN PATIENTS WITH HEPATITIS C;
UNDERSTANDING THE POPULATIONS AT RISK AND REAL-WORLD CARE
MANAGEMENT - Lead author: Michael
Curry, MD
Drug-drug interactions are a concern in the aging US population
and while estimates of possible interactions have been reported,
the actual management of such in patients with HCV is uncertain.
Using two different data sources, this study reported real-world
frequencies of DDIs with pangenotypic DAAs and actions taken,
manifested by pharmacist recommendations and care implemented by
the provider. Potential DDIs (weak, possible, contraindicated) were
identified in 41% GLE-PIB prescribed patients, 27% SOF-VEL, and 53%
SOF-VEL-VOX. However, pharmacist recommendations were largely
limited to contraindicated DDIs and observed for 12% GLE-PIB
prescribed patients, 7% SOF-VEL, and 13% SOF-VEL-VOX. Pharmacist
recommendations were not followed for 15% of patients. Though
prevalence of DDI is very common for HCV treatment and more
frequent in protease-containing regimens, pharmacist
recommendations in the real-world are largely limited to
contraindicated treatment and physician response to recommendations
vary.
About Trio Health
Trio Health's mission is to improve the quality of care in
patient outcomes through coordinating the efforts of all patient
care stakeholders. Their first-of-its-kind Multi-Disease Platform
(MDX) tracks patients throughout the course of their treatment,
giving pharmaceutical/biotechnology companies, specialty pharmacies
and physicians access to information and opportunities that simply
doesn't exist anywhere else. Learn more
at www.triohealth.com.
CONTACT:
For Trio Health:
Eric Bovim
Avisa Partners U.S.
eric.bovim@avisa-partners.com
View original
content:http://www.prnewswire.com/news-releases/trio-health-releases-findings-from-real-world-studies-in-hepatitis-c-and-b-patients-300954889.html
SOURCE Trio Health